STAT3 and cancer: However, the JNK or JAK2 inhibitor could neither augment the anti-cancer effects of pKAL on STAT3 activity (Figure 4A,B), nor on the expressions of CD44, Oct 3/4, β-catenin, and MMP-9 of RT-R-MDA-MB-231 cells (Figure 5).